I love everything about this post. Direct, understandable, and the concluding discussion doesn't equivocate. Plus it underscores my growing belief that patient education shouldn't be all-consuming. A very few times a year -- and more often, every few years -- of getting information like this to discuss with your healthcare teams is much more helpful than treating disease information like it's a headline news feed that has to be consumed constantly. Take the time to digest information like this, it will be much more productive and more likely to remain sane.
Thank you. After my diagnosis 6+ years ago with the kappa-only version of mm, plus GI amyloid, I received CyBorD and did very well but developed severe neuropathy. That led to dara and 5 mg Rev, which kept me at very low numbers; but after seeing MRD numbers not be as low as they could be, I substituted venetoclax for Rev and it has been amazing. Still no relapse, ever, or illness--or sct. I found it interesting that the 11;14 people in the study did not do as well...would be interested in that other discussion you mentioned. Totally agree with staying away from bortezomib!!!
Excellent article and very easy to understand for patients. I concur with your thoughts. I am Newly Diagnosed and underwent Dara KRd 8 cycles. Collected and stored stem cells (as I was MRD -5 at cycle 4) and am happy to report that I am MRD -6 now. As a high risk patient (t4:14 and 1p) I'm so grateful my doctor recommended this treatment plan. I hope to remain in remission for many many years until you extraordinary MM scientists find the cure or a way to permanently and safely manage this disease. Thank you for all you do for the MM community Dr Fonseca.
In the MRD Negativity table, the MIDAS results are on the section/rows for bortezomib. Should these be moved to the carfilzomib combinations section/rows?
I love everything about this post. Direct, understandable, and the concluding discussion doesn't equivocate. Plus it underscores my growing belief that patient education shouldn't be all-consuming. A very few times a year -- and more often, every few years -- of getting information like this to discuss with your healthcare teams is much more helpful than treating disease information like it's a headline news feed that has to be consumed constantly. Take the time to digest information like this, it will be much more productive and more likely to remain sane.
Thanks Greg. You are kind
Thank you. After my diagnosis 6+ years ago with the kappa-only version of mm, plus GI amyloid, I received CyBorD and did very well but developed severe neuropathy. That led to dara and 5 mg Rev, which kept me at very low numbers; but after seeing MRD numbers not be as low as they could be, I substituted venetoclax for Rev and it has been amazing. Still no relapse, ever, or illness--or sct. I found it interesting that the 11;14 people in the study did not do as well...would be interested in that other discussion you mentioned. Totally agree with staying away from bortezomib!!!
I am glad to hear you are doing so well. Indeed, we need to prevent neuropathy!
Excellent article and very easy to understand for patients. I concur with your thoughts. I am Newly Diagnosed and underwent Dara KRd 8 cycles. Collected and stored stem cells (as I was MRD -5 at cycle 4) and am happy to report that I am MRD -6 now. As a high risk patient (t4:14 and 1p) I'm so grateful my doctor recommended this treatment plan. I hope to remain in remission for many many years until you extraordinary MM scientists find the cure or a way to permanently and safely manage this disease. Thank you for all you do for the MM community Dr Fonseca.
Thanks and I am glad you found it clear.
In the MRD Negativity table, the MIDAS results are on the section/rows for bortezomib. Should these be moved to the carfilzomib combinations section/rows?
Thanks for noting. It has been corrected